Share:
PALO ALTO, Calif. and SAN FRANCISCO, Dec. 21, 2020 /PRNewswire/ Autobahn Labs, a virtual incubator partnering with top academic and research institutions to catalyze early-stage drug discovery and development, today announced a strategic collaboration with the University of California San Francisco (UCSF). The organizations will partner to identify promising early science with significant therapeutic potential, forming jointly owned ventures to accelerate the translation of scientific ideas to novel therapeutics. UCSF combines world-class medicine, cutting-edge research, and a strong track record of innovation in drug discovery, said Thomas Novak, PhD, Chief Scientific Officer of Autobahn Labs. We re excited to partner their great science with Autobahn Labs resources and capabilities to spark the development of meaningful new therapies for patients.
Autobahn Labs announces a strategic drug discovery partnership with UCSF
Autobahn Labs, a virtual incubator partnering with top academic and research institutions to catalyze early-stage drug discovery and development, today announced a strategic collaboration with the University of California San Francisco (UCSF).
The organizations will partner to identify promising early science with significant therapeutic potential, forming jointly owned ventures to accelerate the translation of scientific ideas to novel therapeutics. UCSF combines world-class medicine, cutting-edge research, and a strong track record of innovation in drug discovery, said Thomas Novak, PhD, Chief Scientific Officer of Autobahn Labs. We re excited to partner their great science with Autobahn Labs resources and capabilities to spark the development of meaningful new therapies for patients.
As COVID Vaccines Fast Approach for Adults, Researchers Prepare for Large-Scale Growth in Pediatrics
Share Article
Pediatric vaccine development has been one of the fastest growing areas in clinical research prior to the COVID-19 pandemic. Platinum Research Network has been actively supporting Phase I-III COVID-19 vaccine trials in adults and is fully prepared for upcoming trials in pediatric age groups. These trials are necessary to efficiently bring life-changing vaccines to the market.
Platinum Research Network
Kip McKenzie, President of Tekton Research, states, “Through the strength and collaborative relationships with Sponsors and CRO’s and extensive experience with enrollment of pediatric studies, we are prepared to successfully enroll pediatric COVID-19 trials.”
Share this article
Share this article
LA JOLLA, Calif., Dec. 15, 2020 /PRNewswire/ Alume Biosciences, Inc. (Alume) announced today that it has been awarded a $2.5M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). This grant will support Alume s clinical development of its novel nerve illumination technology in surgery. The Principal Investigators on this grant are Michael Whitney, PhD, Scientific Co-Founder and Vice President of Discovery and Brett Berman, MD, Co-Founder and Chief Medical Officer at Alume.
Alume previously received a Phase I SBIR grant in 2019 from the NINDS to develop nerve illumination agents for surgical use. The Phase II SBIR grant is a follow-on 2–year award that will support testing of Alume s fluorescent nerve targeting agent in an ongoing Phase 1/2 clinical trial in patients undergoing Head and Neck Surgery. Alume s technolog
Share:
NEW YORK, Dec. 14, 2020 /PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today the initiation of a NurOwn® (MSC-NTF cells) Expanded Access Program (EAP) for patients with amyotrophic lateral sclerosis (ALS) who completed the Company s recently concluded pivotal Phase 3 clinical trial and meet specific eligibility requirements.
The protocol for the EAP was developed in partnership with the United States Food and Drug Administration (FDA) to provide access to NurOwn for Phase 3 clinical trial participants who meet specific eligibility criteria. Initially, patients less severely affected by ALS, as measured by the Revised ALS Functional Rating Scale (ALSFRS-R), will be the first to receive treatment. This approach is informed by recently announced topline data from the Company s Phase 3 clinical trial. According to the